Literature DB >> 9703782

Prognostic impact of tumor biological factors on survival in node-negative breast cancer.

N Harbeck1, P Dettmar, C Thomssen, B Henselmann, W Kuhn, K Ulm, F Jänicke, H Höfler, H Graeff, M Schmitt.   

Abstract

Tumor biological factors uPA, PAI-1, cathepsin D, S-phase fraction (SPF), MIB1 (Ki-67), p53, and HER-2/neu were assessed in 100 node-negative breast cancer patients. Their prognostic impact on disease-free (DFS) as well as overall survival (OS) was compared to that of traditional factors tumor size, grading, and steroid hormone receptor status. Antigen levels of uPA, its inhibitor PAI-1, and cathepsin D were determined in tumor tissue extracts by immunoenzymatic methods. SPF was determined by flow cytofluorometry, MIB1, p53, and HER-2/neu by immunohistochemistry in adjacent routinely formalin-fixed paraffin sections. Median follow-up in all patients still alive at time of analysis was 76 months. Univariate analysis determined PAI-1 (p = 0.0001), uPA (p = 0.0437), MIB1 (p = 0.0214), and SPF (p = 0.0248) as statistically significant prognostic factors for DFS. In contrast, tumor size, steroid hormone receptor status, grading, p53, HER-2/neu, and cathepsin. D failed to be of prognostic value. In multivariate analysis, including the statistically significant prognostic factors PAI-1, uPA, MIB1, and SPF, only PAI-1 (p = 0.0003, relative risk: 4.7) proved to be of independent statistical significance for DFS. Regarding OS, PAI-1 was the only statistically significant prognostic factor in univariate (p = 0.0001) as well as multivariate analysis (p = 0.0000, relative risk: 7.1). Thus, factors describing the invasive and metastatic capacity of tumor cells (uPA, PAI-1) and factors related to their proliferative activity (SPF, MIB1) provide valuable prognostic information in node-negative breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703782

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

Authors:  E Dublin; A Hanby; N K Patel; R Liebman; D Barnes
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

Authors:  P Nagy; A Jenei; S Damjanovich; T M Jovin; J Szölôsi
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

3.  [The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma].

Authors:  B Hundsdorfer; H-F Zeilhofer; K P Bock; P Dettmar; M Schmitt; H-H Horch
Journal:  Mund Kiefer Gesichtschir       Date:  2004-02-06

Review 4.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

5.  Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study.

Authors:  William E Gillanders; Kaidi Mikhitarian; Renee Hebert; Patrick D Mauldin; Yuko Palesch; Christian Walters; Marshall M Urist; G Bruce Mann; Gerard Doherty; Virginia M Herrmann; Arnold D Hill; Oleg Eremin; Mohamed El-Sheemy; Richard K Orr; Alvaro A Valle; Michael A Henderson; Robert L Dewitty; Sonia L Sugg; Eric Frykberg; Karen Yeh; Richard M Bell; John S Metcalf; Bruce M Elliott; Thomas Brothers; Jay Robison; Michael Mitas; David J Cole
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

6.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

7.  Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.

Authors:  Eva J Kantelhardt; Martina Vetter; Marcus Schmidt; Corinne Veyret; Doris Augustin; Volker Hanf; Christoph Meisner; Daniela Paepke; Manfred Schmitt; Fred Sweep; Gunter von Minckwitz; Pierre-Marie Martin; Fritz Jaenicke; Christoph Thomssen; Nadia Harbeck
Journal:  BMC Cancer       Date:  2011-04-16       Impact factor: 4.430

8.  Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.

Authors:  Christian Schindlbeck; Theresa Kampik; Wolfgang Janni; Brigitte Rack; Udo Jeschke; Stan Krajewski; Harald Sommer; Klaus Friese
Journal:  Breast Cancer Res       Date:  2005-11-24       Impact factor: 6.466

9.  Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.

Authors:  N Harbeck; P Dettmar; C Thomssen; U Berger; K Ulm; R Kates; H Höfler; F Jänicke; H Graeff; M Schmitt
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

10.  C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.

Authors:  Claus M Schlotter; Ulf Vogt; Ulrich Bosse; Berthold Mersch; Katja Wassmann
Journal:  Breast Cancer Res       Date:  2003-01-13       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.